A Phase 2 Trial of Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk MDS

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Uday Popat, Chitra M. Hosing, Roland L. Bassett, Amin Majid Alousi, Gheath Alatrash, Yosra M. Aljawai, Qaiser Bashir, George L. Chen, Warren Benjamin Fingrut, Jin S. Im, Partow Kebriaei, David Marin
+12 more Yago L. Nieto, Amanda Leigh Olson, Betül Oran, Muzaffar H. Qazilbash, Jeremy Ramdial, Neeraj Y. Saini, Portia Smallbone, Samer A. Srour, Alexandre Bazinet, Guillermo Garcia‐Manero, Richard E. Champlin, Elizabeth J. Shpall
DOI: 10.1016/j.jtct.2025.12.086
Cited by: 0

Fields of Study & Subjects

Hematopoietic Stem Cell Transplantation Acute Myeloid Leukemia Research Multiple and Secondary Primary Cancers

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S57–S57
Publication date
1 February 2026
Language
EN